The mixture of selinexor plus ruxolitinib met the primary co-primary endpoint demonstrating a statistically vital enchancment of spleen quantity discount ...
TLX597-Tx is a PSMA-targeting small molecule radioligand remedy (RLT) candidate, designed to enhance quality-of-life and efficacy in earlier-stage prostate most ...